FabI (enoyl-acyl carrier protein reductase): a key target for the development of antibacterial agents
Year: 2026
Type: article
Abstract: Antimicrobial resistance (AMR) is currently a serious threat to human health. Consequently, the development of new antibacterial agents targeting underexplored bacterial pathways and thereby circumventing existing resistance mechanisms is urgent. The widely conserved bacterial type II fatty acid synthesis (FAS-II) pathway represents an attractive target to tackle antimicrobial resistance. FAS-II is mediated by a series of Fab enzymes. Among these, enoyl-acyl carrier protein reductase (ENR) catalyzes the reduction of a double bond in enoyl-ACP to acyl-ACP, a crucial step in bacterial fatty acid biosynthesis. In humans, fatty acid biosynthesis occurs via a distinct multi-enzyme FAS-I complex, making FAS-II enzymes promising targets for the development of new antibacterial agents. FabI is the most extensively characterized ENR and is widely distributed among clinically relevant bacterial pathogens. Besides FabI, alternative ENRs, including FabK, FabL, FabV, and the mycobacterial homolog InhA, have been identified in different microorganisms. FabI represents a validated antibacterial target, with several covalent and non-covalent FabI inhibitors having emerged as potential antibiotics. Among these, advanced clinical candidates such as afabicin and nilofabicin have demonstrated the therapeutic potential of ENR inhibition. This review summarizes the FabI structure, the catalytic mechanism, the ENR diversity, and the major classes of reported FabI inhibitors. Taken together, these insights provide a foundation for the rational development of next-generation antibacterial agentes. This review summarizes the FabI structure, the catalytic mechanism, the ENR diversity, and the major classes of reported FabI inhibitors. Taken together, these insights provide a foundation for the rational development of next-generation antibacterial agentes.
Source: Frontiers in Drug Discovery
Authors: Raquel Goes de Castro(Conceptualization, Investigation, Visualization, Writing – original draft), Fernanda Kelly Marcelino e Oliveira(Conceptualization, Investigation, Visualization, Writing – original draft), Gabriel Corrêa Veríssimo(Investigation, Visualization, Writing – review & editing), Mateus Sá Magalhães Serafim(Conceptualization, Investigation, Visualization, Writing – original draft, Writing – review & editing), Débora Maria Abrantes Costa(Conceptualization, Funding acquisition, Investigation, Resources, Supervision, Writing – original draft, Writing – review & editing)
Institution: Universidade Federal de Minas Gerais
Language: English
Subfield: Applied Microbiology and Biotechnology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,353
Awards: REDE MINEIRA DE PESQUISA E INOVAÇÃO EM QUÍMICA MEDICINAL - RMQM, G3252129808, DESENVOLVIMENTO DE FÁRMACOS BASEADO NA ESTRUTURA: PRODUÇÃO E CARACTERIZAÇÃO DA ESTRUTURA TRIDIMENSIONAL DE POTENCIAIS ALVOS MOLECULARES EM COMPLEXO COM CANDIDATOS A FÁRMACOS CONTRA A COVID-19 E CONTRA BACTÉRIAS MULTIRRESISTENTES, G7434043568, OTIMIZAÇÃO DE POTENTES INIBIDORES MULTI-FLAVIVÍRUS CANDIDATOS À FARMACO: CARACTERIZAÇÃO ESTRUTURAL E BIOLÓGICA DA ATIVIDADE ANTIVIRAL E ENZIMÁTICA CONTRA A PROTEASE NS3PRO DE DENGUE, ZIKA E FEBRE AMARELA, G859436129
OpenAlex ID: W7236182034
